Search found 76 matches

by ton
Fri Jun 28, 2019 10:22 am
Forum: Drug Pipeline
Topic: Could be this time?
Replies: 3
Views: 1818

Re: Could be this time?

Multiple sclerosis: Endogenous retrovirus HERV-W key to nerve tissue damage Neurology: Publication in PNAS 27 June 2019 – Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) affecting brain and spinal cord. In collaboration with colleagues from the USA and Canada, a...
by ton
Sat Dec 22, 2018 1:27 pm
Forum: Drug Pipeline
Topic: Could be this time?
Replies: 3
Views: 1818

Re: Could be this time?

by ton
Mon Mar 26, 2018 6:24 am
Forum: Drug Pipeline
Topic: Could be this time?
Replies: 3
Views: 1818

Could be this time?

The Black Swan we are waiting for?: http://www.geneuro.com/data/news/geneur ... -ms-en.pdf
by ton
Tue Dec 20, 2016 8:42 am
Forum: Drug Pipeline
Topic: THE MISSING LINK?
Replies: 0
Views: 2251

THE MISSING LINK?

Unknown Soldiers: UVA Discovers Powerful Defenders of the Brain

Please take a look:

https://news.virginia.edu/content/unkno ... ders-brain
by ton
Mon Sep 19, 2016 8:43 am
Forum: Drug Pipeline
Topic: TRENDING TOPIC, BUT PRELIMINARY
Replies: 0
Views: 2687

TRENDING TOPIC, BUT PRELIMINARY

Inhibiting the Autoimmune Response to Treat Multiple Sclerosis

http://www.bioe.umd.edu/news/news_story.php?id=9958

Full text:
http://www.cell.com/cell-reports/fulltext/S2211-1247(16%2931097-X
by ton
Sat Sep 17, 2016 7:19 am
Forum: Stem Cells
Topic: STEMCELL TREATMENT FOR M.S
Replies: 1
Views: 2582

Re: STEMCELL TREATMENT FOR M.S

HI SEEVA!, one step closer... "Just keep swimming", as Doris says. here some aditional info (not especific for ms but very interesing too): Top 10 Google Stem Cell News Stories: Perspectives http://www.ipscell.com/2016/09/top-10-google-stem-cell-news-stories-perspectives/ source: The Niche Knoepfler...
by ton
Fri Sep 02, 2016 8:26 am
Forum: Biotin (Qizenday, Cerenday, MD1003)
Topic: SHORT NEWS FROM MEDDAY
Replies: 2
Views: 2967

Re: SHORT NEWS FROM MEDDAY

Friday, September 02, 2016 MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal Paris, France, 2 September 2016 - MedDay, a biotechnology company focused on the treatment of nervous system disorders, announces the online publication of results from the previou...
by ton
Mon Aug 22, 2016 6:31 am
Forum: Stem Cells
Topic: “If You See Something, Say Something”
Replies: 0
Views: 2161

“If You See Something, Say Something”

Editorial by Deborah Sweet on encouraging readers to take action on stem cell clinics.
(Cell Stem Cell)

http://www.cell.com/cell-stem-cell/fulltext/S1934-5909(16%2930209-0
by ton
Tue Aug 09, 2016 4:14 pm
Forum: Stem Cells
Topic: GOOD NEWS FROM ISRAEL.!!
Replies: 10
Views: 5346

Re: GOOD NEWS FROM ISRAEL.!!

Paul Alster from The Jerusalem Post wrote this encouraging report.

http://www.jpost.com/Jerusalem-Report/O ... ine-459639
by ton
Tue Jun 07, 2016 8:20 am
Forum: Drug Pipeline
Topic: Biogen Opicinumab(Anti-LINGO-1) Fails Phase 2 Study of in MS
Replies: 0
Views: 2504

Biogen Opicinumab(Anti-LINGO-1) Fails Phase 2 Study of in MS

:sad: Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis

http://media.biogen.com/press-release/i ... anti-lingo
by ton
Wed Jun 01, 2016 11:19 am
Forum: Gene Therapy
Topic: A mutation increases 70% the risk of multiple sclerosis!
Replies: 3
Views: 3892

A mutation increases 70% the risk of multiple sclerosis!

This is the first genetic alteration associated with less frequent familial cases. A mutation in the gene NR1H3 increases by 70% the risk of developing multiple sclerosis, as described today in Neuron by a team from the University of British Columbia in Vancouver (Canada). Here is the link: http://...
by ton
Wed May 25, 2016 7:47 am
Forum: Biotin (Qizenday, Cerenday, MD1003)
Topic: SHORT NEWS FROM MEDDAY
Replies: 2
Views: 2967

SHORT NEWS FROM MEDDAY

Wednesday, May 25, 2016 MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial Paris, France, 25 May 2016 - MedDay, a biotechnology company focused on the treatment of nervous system disorders, announces that an oral presentation entitled “High dos...